In combination with our findings from the mouse model and the human brain samples, it is therefore conceivable to test in future studies whether targeting mitochondrial and autophagy-related deficits might be a beneficial therapeutic strategy for treating WS and other GTF2I-related pathologies. Here, GTF2I is linked to Werner syndrome.